Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019
![](/report_cover/8047/pyoderma-gangrenosum-pg-pipeline-insight-2019_en.gif)
This report can be delivered to the clients within 24 Hours
"Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyoderma Gangrenosum pipeline landscape is provided which includes the disease overview and Pyoderma Gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma Gangrenosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyoderma Gangrenosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pyoderma Gangrenosum Understanding
Pyoderma gangrenosum (PG) is an inflammatory skin disorder that is characterized by small, red bumps or blisters (papules or nodules) that eventually erode to form swollen open sores (ulcerations). The size and depth of the ulcerations vary greatly, and they are often extremely painful. In approximately 50 percent of cases, PG occurs secondary to another disorder such as inflammatory bowel disease. The exact cause of PG is unknown (idiopathic). Pyoderma gangrenosum usually starts with a small, red bump on your skin, which may resemble a spider bite. Within days, this bump can develop into a large, painful open sore. These small growths eventually develop into swollen, open sores (ulcerations) with a well-defined blue or violet-colored border. The size and depth of ulcerations vary. The exact cause of pyoderma gangrenosum is unknown (idiopathic) although it is suspected to be an autoimmune disease.
Pyoderma Gangrenosum Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pyoderma Gangrenosum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pyoderma Gangrenosum pipeline report covers 7+ companies. Some of the key players include InflaRx (IFX 1), Eli Lilly (Ixekizumab) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pyoderma Gangrenosum Analytical Perspective by DelveInsight
Scope of the report
"Pyoderma Gangrenosum (PG) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyoderma Gangrenosum pipeline landscape is provided which includes the disease overview and Pyoderma Gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma Gangrenosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyoderma Gangrenosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pyoderma Gangrenosum Understanding
Pyoderma gangrenosum (PG) is an inflammatory skin disorder that is characterized by small, red bumps or blisters (papules or nodules) that eventually erode to form swollen open sores (ulcerations). The size and depth of the ulcerations vary greatly, and they are often extremely painful. In approximately 50 percent of cases, PG occurs secondary to another disorder such as inflammatory bowel disease. The exact cause of PG is unknown (idiopathic). Pyoderma gangrenosum usually starts with a small, red bump on your skin, which may resemble a spider bite. Within days, this bump can develop into a large, painful open sore. These small growths eventually develop into swollen, open sores (ulcerations) with a well-defined blue or violet-colored border. The size and depth of ulcerations vary. The exact cause of pyoderma gangrenosum is unknown (idiopathic) although it is suspected to be an autoimmune disease.
Pyoderma Gangrenosum Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pyoderma Gangrenosum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pyoderma Gangrenosum pipeline report covers 7+ companies. Some of the key players include InflaRx (IFX 1), Eli Lilly (Ixekizumab) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pyoderma Gangrenosum Analytical Perspective by DelveInsight
- In-depth Pyoderma Gangrenosum Commercial Assessment of products
- Pyoderma Gangrenosum Clinical Assessment of products
Scope of the report
- The Pyoderma Gangrenosum report provides an overview of therapeutic pipeline activity for Pyoderma Gangrenosum across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Pyoderma Gangrenosum therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Pyoderma Gangrenosum Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pyoderma Gangrenosum
- Establish a comprehensive understanding of the current pipeline scenario across Pyoderma Gangrenosum to formulate effective R&D strategies
- Assess challenges and opportunities that influence Pyoderma Gangrenosum R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Pyoderma Gangrenosum in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pyoderma Gangrenosum to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. PYODERMA GANGRENOSUM
2.1. Pyoderma Gangrenosum Disease Overview
2.2. Pyoderma Gangrenosum History
2.3. Pyoderma Gangrenosum Symptoms
2.4. Pyoderma Gangrenosum Causes
2.5. Pyoderma Gangrenosum Pathophysiology
2.6. Pyoderma Gangrenosum Diagnosis
2.6.1. Diagnostic Guidelines
3. PYODERMA GANGRENOSUM CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PYODERMA GANGRENOSUM- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Pyoderma Gangrenosum Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Pyoderma Gangrenosum Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PYODERMA GANGRENOSUM PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PYODERMA GANGRENOSUM-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. IFX 1- InflaRx
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Ixekizumab- Eli Lilly
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PYODERMA GANGRENOSUM KEY COMPANIES
8.1. AbbVie
8.2. XBiotech
8.3. InflaRx
8.4. XOMA
8.5. Arena Pharmaceuticals
8.6. Eli Lilly
8.7. Aclaris Therapeutics
9. PYODERMA GANGRENOSUM KEY PRODUCTS
9.1. Adalimumab
9.2. Bermekimab
9.3. IFX 1
9.4. Gevokizumab
9.5. Etrasimod
9.6. Ixekizumab
9.7. ATI 450
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PYODERMA GANGRENOSUM- UNMET NEEDS
12. PYODERMA GANGRENOSUM- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. PYODERMA GANGRENOSUM
2.1. Pyoderma Gangrenosum Disease Overview
2.2. Pyoderma Gangrenosum History
2.3. Pyoderma Gangrenosum Symptoms
2.4. Pyoderma Gangrenosum Causes
2.5. Pyoderma Gangrenosum Pathophysiology
2.6. Pyoderma Gangrenosum Diagnosis
2.6.1. Diagnostic Guidelines
3. PYODERMA GANGRENOSUM CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PYODERMA GANGRENOSUM- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Pyoderma Gangrenosum Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Pyoderma Gangrenosum Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PYODERMA GANGRENOSUM PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PYODERMA GANGRENOSUM-PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. IFX 1- InflaRx
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Ixekizumab- Eli Lilly
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PYODERMA GANGRENOSUM KEY COMPANIES
8.1. AbbVie
8.2. XBiotech
8.3. InflaRx
8.4. XOMA
8.5. Arena Pharmaceuticals
8.6. Eli Lilly
8.7. Aclaris Therapeutics
9. PYODERMA GANGRENOSUM KEY PRODUCTS
9.1. Adalimumab
9.2. Bermekimab
9.3. IFX 1
9.4. Gevokizumab
9.5. Etrasimod
9.6. Ixekizumab
9.7. ATI 450
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PYODERMA GANGRENOSUM- UNMET NEEDS
12. PYODERMA GANGRENOSUM- FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Pyoderma Gangrenosum Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Pyoderma Gangrenosum Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Pyoderma Gangrenosum Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Pyoderma Gangrenosum Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Pyoderma Gangrenosum Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
AbbVie
XBiotech
InflaRx
Janssen Biotech
AbbVie
XOMA
Arena Pharmaceuticals
Eli Lilly
Aclaris Therapeutics
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Pyoderma Gangrenosum companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Pyoderma Gangrenosum Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
AbbVie
XBiotech
InflaRx
Janssen Biotech
AbbVie
XOMA
Arena Pharmaceuticals
Eli Lilly
Aclaris Therapeutics